Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Pilot Study: Changes of Intestinal Microbiota of Patients With Non-small Cell Lung Cancer in Response to Osimertinib Therapy

10 Nov 2020

Abstract excerpt

Osimertinib contributes to the higher efficacy and few intestinal side effects in non-small cell lung cancer (NSCLC) patients with T790M mutation. Previous studies has reported that intestinal microbiota play important roles in drug efficacy and toxicity. However, we have known less about the changes of intestinal microbiota in response to osimertinib therapy. In this pilot study, we used longitudinal sampling...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gut microbiota and health
Share to Lung Cancer Treatments and Mutations
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33240237
DOI: 10.3389/fmicb.2020.583525

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Pilot Study: Changes of Intestinal Microbiota of Patients With Non-small Cell Lung Cancer in Response to Osimertinib TherapyPMID 33240237Read ↗

Gut Microbiota a Novel Source of Biomarkers for Immunotherapy in Non-small Cell Lung Cancer (NSCLC)Semantic proximity Read ↗

Gut Microbiota Signatures with Potential Clinical Usefulness in Colorectal and Non-small Cell Lung CancersSemantic proximity Read ↗

Gut Microbiota Signatures with Potential Clinical Usefulness in Colorectal and Non-Small Cell Lung CancersSemantic proximity Read ↗

Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancerSemantic proximity Read ↗

Microbiome and EGFR-mutant non-small cell lung cancer: a complex interplay.Semantic proximity Read ↗

Catalog of gut microbiota alterations associated with anticancer therapies across multiple cancer typesSemantic proximity Read ↗

Metagenomic and Metabolomic Correlates of Immunotherapy Response in Non-Small Cell Lung CancerSemantic proximity Read ↗

Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

Analysis of Gut Microbiota Signature and Microbe-Disease Progression Associations in Locally Advanced Non-Small Cell Lung Cancer Patients Treated With Concurrent ChemoradiotherapySemantic proximity Read ↗

Distinct gut virome profiles are associated with response to anti-PD-1 therapy in non-small cell lung cancerSemantic proximity Read ↗

Exploring Gut Microbiome in Predicting the Efficacy of Immunotherapy in Non-Small Cell Lung CancerSemantic proximity Read ↗

Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer—A reviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.